Polymorphism of the L1 capsid gene and persistence of human papillomavirus type 52 infection in women at high risk or infected by HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 1, 2007, Pages 61-65

  Gagnon, Simon ^a   Hankins, Catherine ^b,c,f   Money, Deborah ^d,f   Pourreaux, Karina ^b   Conners, Janet ^f   Grimshaw, Rob ^f   Haase, David ^f   Johnston, Lynn ^f   Schlech, Wally ^f   Yuzicappi Fayant, Arlo ^f   Landis, Stephen ^f   Smaill, Fiona ^f   Austin, Tom ^f   Hammerberg, Ole ^f   Ralph, Ted ^f   Coutlée, François ^a,b,e,f   Falutz, Julian ^f   Ferenczy, Alex ^f   Klein, Marina ^f   Labrecque, Louise ^f   Lapointe, Normand ^f   Lalonde, Richard ^f   MacLeod, John ^f   Noël, Grégoire ^f   Perron, Chantal ^f   Routy, Jean Pierre ^f   Toma, Emil ^f   Touchie, Claire ^f   Victor, Garry ^f   Coté, Louise ^f   Senay, Hélène ^f   Trottier, Sylvie ^f   Williams, Kurt ^f   Piché, Alain ^f   Sandre, Roger ^f   Binder, Louise ^f   Keystone, Donna ^f   Phillips, Anne ^f   Rachlis, Anita ^f   Salit, Irving ^f   Wagner, Cheryl ^f   Sharon, ^f   Walmsley, ^f   Braitstein, Paula ^f   Burdge, David ^f   Harris, Marianne ^f   Montaner, Julio ^f   Franco, Eduardo ^b   more..

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Hôpital Notre Dame du Centre Hospitalier de l'Université de Montréal ^*

Author keywords

Cervical cancer; HIV; HPV; Polymorphism; Vaccine

Indexed keywords

CALGRANULIN;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DNA POLYMORPHISM; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 52; IMMUNE RESPONSE GENE; MAJOR CLINICAL STUDY; PAPILLOMA VIRUS; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VERRUCA VULGARIS; VIRUS CAPSID;

ADULT; CAPSID PROTEINS; COHORT STUDIES; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; RISK; VAGINA;

EID: 33846004460     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000247226.45375.01     Document Type: Article

References (17)

1. Palefsky JM. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J Natl Cancer Inst. 1998;23:15-20.
2. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265.
3. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000;283:1031-1037.
4. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106-3114.
5. Ferenczy A, Franco EL. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 2002;3:11-16.
6. Giannoudis A, Herrington CS. Human papillomavirus variants and squamous neoplasia of the cervix. J Pathol. 2001;193:295-302.
7. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
8. Coutlée F, Hankins C, Lapointe N, et al. Comparison between vaginal tampon and cervicovaginal lavage specimens collection for detection of human papillomavirus DNA by the polymerase chain reaction. J Med Virol. 1997;51:42-47.
9. Aho J, Hankins C, Tremblay C, et al. Genomic polymorphism of human papillomavirus type 52 predisposes to persistent infection. J Infect Dis. 2004;190:46-52.
10. Aho J, Hankins C, Tremblay C, et al. Molecular analysis of human papillomavirus type 52 isolates detected in the genital tract of HIV-seropositive and seronegative women. J Infect Dis. 2003;188:1517-1527.
11. Hankins C, Coutlee F, Lapointe N, et al. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. CMAJ. 1999;160:185-191.
12. Hankins C, Lapointe N, Walmsley S. The Canadian Women's HIV Study Group: participation in clinical trials among women living with HIV in Canada. CMAJ. 1998;159:1359-1365.
13. Stewart AC, Eriksson AM, Manos MM, et al. Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol. 1996;70:3127-3136.
14. Chen XS, Garcea RL, Goldberg I, et al. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000;5:557-567.
15. Olcese VA, Chen Y, Schlegel R, et al. Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol. 2004;4,29:1-11.
16. Ellis JR, Etherington I, Galloway D, et al. Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16. Lancet. 1997;349:1069-1070.
17. Shimoda K, Lorincz AT, Temple GF, et al. Human papillomavirus type 52: a new virus associated with cervical neoplasia. J Gen Virol. 1988;69:2925-2928.